Table 6. Studies evaluating cfDNA EGFR sensitive mutations in patients with NSCLC.
| Study | Detection Method | Mutated patients (n) | Sensitivity (%) (n/total) | Specificity (%) (n/total) | Concordance (%) (n/total) |
|---|---|---|---|---|---|
| Bai et al. [10] | DHPLC | 77 | 81.8 (63/77) | 89.5 (137/153) | 74.0 (200/230) |
| Huang et al. [53] | DHPLC | 296 | 63.5 (188/296) | 84.6 (445/526) | 77.0 (633/822) |
| Liu et al. [35] | ARMS | 40 | 67.5 (27/40) | 100.0 (46/46) | 84.9 (73/86) |
| Kim et al. [54] | PNA-PCR | 35 | 17.1 (6/35) | 100.0 (5/5) | 27.5 (11/40) |
| Zhao et al. [55] | Mutant-enriched PCR | 45 | 35.6 (16/45) | 95.5 (63/66) | 71.2 (79/111) |
| Wang et al. [36] | ARMS | 68 | 22.1 (15/68) | 97.0 (64/66) | 59.0 (79/134) |
| Jing et al. [56] | HRMA | 45 | 66.4 (29/45) | 97.3 (73/75) | 85.0 (102/120) |
| Weber et al. [57] | Cobas EGFR test | 28 | 60.7 (17/28) | 96.4 (162/168) | 91.3 (179/196) |
| Yu et al. [58] | ddPCR | 93 | 61.3 (57/93) | 96.7 (118/122) | 81.4 (175/215) |
| Zhu et al. [59] | ddPCR | 37 | 81.1 (30/37) | 97.0 (131/135) | 93.6 (161/172) |
Abbreviations: DHPLC, denaturing high-performance liquid chromatography; ARMS, amplification refractory mutation system; PNA, peptide nucleic acid; PCR, polymerase chain reaction; HRMA, high resolution melting analysis.